Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$14.19 USD
+0.22 (1.57%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $14.18 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.19 USD
+0.22 (1.57%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $14.18 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Pacira's Study on Exparel Label Expansion Meets Endpoints
by Madhu Goel
Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.
Cara (CARA) Up on IDMC's Recommendation to Continue Trial
by Zacks Equity Research
Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.
Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com
by Zacks Equity Research
Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com
In Search of an Earnings Beat? Play These Top 5 Stocks
by Sanghamitra Saha
These top-ranked stocks may surpass bottom-line estimates in their next release.
Why Is Pacira (PCRX) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly (LLY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Momentum Stocks to Buy for November 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th
Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3
Pacira (PCRX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 342.86% and 5.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.
Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares rise 6% on the day, amid huge volumes.
Catalyst Pharmaceuticals (CPRX) Catches Eye: Stock Jumps 6.3%
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status
by Zacks Equity Research
Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
by Zacks Equity Research
Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.
Molecular Templates Surges 50%, Inks Cancer Deal With Takeda
by Zacks Equity Research
Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.
Implied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Pacira Pharmaceuticals (PCRX) stock based on the movements in the options market lately.
United Therapeutics In-Licenses Rights to IPF Candidate
by Zacks Equity Research
United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.
Ironwood Stock Up, Heart Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
by Indrajit Bandyopadhyay
Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.
KemPharm Posts Positive Top-Line Results on KP415 Prodrug
by Zacks Equity Research
KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.
Endocyte (ECYT) Soars: Stock Adds 11.4% in Session
by Zacks Equity Research
Endocyte (ECYT) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
Biogen Begins Phase III Study on Ischemic Stroke Candidate
by Zacks Equity Research
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Pacira (PCRX) Rides High on Robust Exparel Performance
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.